Genmab A/S (0MGB.IL)
IOB - IOB Delayed price. Currency in DKK
Add to watchlist
At close: 05:33PM BST
| Previous close | 1,935.75 |
| Open | 1,933.00 |
| Bid | 1,911.00 x 0 |
| Ask | 1,990.50 x 0 |
| Day's range | 1,920.00 - 1,950.00 |
| 52-week range | 1,696.50 - 2,814.00 |
| Volume | |
| Avg. volume | 13,653 |
| Market cap | 156.217B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | 27.56 |
| EPS (TTM) | 70.77 |
| Earnings date | 01 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksGMAB vs. CSLLY: Which Stock Is the Better Value Option?
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
Globe NewswireGenmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
Company Announcement Net sales of DARZALEX® in the second quarter of 2024 totaled USD 2,878 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; July 17, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson we
ZacksGMAB or TECH: Which Is the Better Value Stock Right Now?
GMAB vs. TECH: Which Stock Is the Better Value Option?
© 2024 Yahoo. All rights reserved.